Results 151 to 160 of about 54,917 (299)

SGLT2 inhibitor

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
Nishiyama, Akira, Hitomi, Hirofumi, Nakano, Daisuke   +2 more
openaire   +2 more sources

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

Diabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo, Bianca Aparecida Siqueira, Luiz Felipe Azevedo Marques, Lucas Silva Mello, Fernando Augusto Lima Marson   +4 more
wiley   +1 more source

Baseline monocyte SGLT2 mRNA expression and changes in the fibrosis-4 index after luseogliflozin treatment in participants with type 2 diabetes and MASLD. [PDF]

Diabetol Int
Okuma H.
europepmc   +1 more source

Multisystem developmental abnormalities and insulin resistance in ADTKD‐HNF1B with the p.E105K variant: A clinical conundrum

Diabetic Medicine, EarlyView.
Abstract Aims HNF1B variants cause autosomal dominant tubulointerstitial kidney disease (ADTKD‐HNF1B), but the phenotypic spectrum of variants of uncertain significance (VUS) remains incompletely defined. We aimed to characterise the multisystem phenotype associated with the HNF1B p.E105K variant and to examine the mechanism underlying insulin ...
YunZe Wang, KangChun Xu, PengFei Liu, Bin Wang, Yan Yang, ShanZhai Wei   +5 more
wiley   +1 more source

Participant and physician perspectives on the use of SGLT2 inhibitors in type 1 diabetes

Diabetic Medicine, EarlyView.
Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLT2i) have proven cardiorenal benefits in type 2 diabetes and are promising as adjunct‐to‐insulin therapy in participants with type 1 diabetes (T1D). However, clinical use in T1D has been limited owing to a lack of regulatory approval and the augmented risk of diabetic ketoacidosis (DKA ...
Julia Fielden, Pam Leblanc, Chloe Parezanovic, Vikas S. Sridhar, Bruce A. Perkins, David Z. Cherney, David J. T. Campbell   +6 more
wiley   +1 more source

Trends in Healthcare Costs in Heart Failure and Its Clinical Phenotypes During the Implementation of SGLT2 Inhibitors: A Finnish Registry Study

ClinicoEconomics and Outcomes Research
Johan Liseth Hansen,1,2 Miikka Tarkia,3 Marija Vasilevska,1 Patrik Sandin,1 Eralda Asllanaj,4 Karlijn Wammes,4 Johan Mesterton,1,5 KE Juhani Airaksinen6 1Quantify Research, Stockholm, Sweden; 2Department of Health Management and Health Economics ...
Hansen JL, Tarkia M, Vasilevska M, Sandin P, Asllanaj E, Wammes K, Mesterton J, Airaksinen KEJ   +7 more
doaj  

Genetically Proxied SGLT2 Inhibition and Risk of Epilepsy: A Mediation Mendelian Randomization Study of Circulating Metabolites. [PDF]

Biomedicines
Chang M, Li J, Gu F, Wu X, Song B, Chen Z, Wang Z.   +6 more
europepmc   +1 more source

The role of sex and ethnicity in the variability of estimated glomerular filtration rate (eGFR) in people with type 1 diabetes

Diabetic Medicine, EarlyView.
Exploring Sex and Ethnicity Differences in eGFR for People with Type I Diabetes. Abstract Aims To examine sex‐based differences in estimated glomerular filtration rate (eGFR) trajectories for people with type 1 diabetes (T1D) over 10 years and to test the hypothesis that sex and ethnicity interaction predicts eGFR decline.
Salma Ayis, Murat Ozdede, Luigi Gnudi, Thamer Alobaid, Panagiotis Pavlou, Anastasios Mangelis, Nikolaos Fountoulakis, Aicha Goubar, Janaka Karalliedde   +8 more
wiley   +1 more source

Use of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors in Incident Hyponatremia in Patients with Type 2 Diabetes: Multicenter Target Trial Emulations. [PDF]

Clin Pharmacol Ther
Lin YH, Tsai DH, Hsieh MH, Lee CC, Tseng CC, Wang MC, Lai EC, Liu KH.   +7 more
europepmc   +1 more source